Moreover, Oroxylin A's effect on CML cells was partly attributed to the blocking of β-catenin translocation to nucleus and decreasing P-gp transcription, a possible target gene of β-catenin. This evidence concerns the gene PGP and chronic myelogenous leukemia, BCR-ABL1 positive.